Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy

被引：55

作者：

Gouda, M. A. ^{[1
,2
]}

Subbiah, V. ^{[1
,3
,4
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Dept Invest Canc Therapeut, Houston, TX 77030 USA

[2] Menoufia Univ, Dept Clin Oncol, Fac Med, Menoufia, Egypt

[3] Univ Texas MD Anderson Canc Ctr, Div Pediat, Houston, TX 77030 USA

[4] Univ Texas MD Anderson Canc Ctr, MD Anderson Canc Network, Houston, TX 77030 USA

来源：

ESMO OPEN | 2023年 / 8卷 / 02期

基金：

美国国家卫生研究院;

关键词：

BRAF; MEK; cancer; precision oncology; targeted therapy; DABRAFENIB PLUS TRAMETINIB; CELL LUNG-CANCER; OPEN-LABEL; SINGLE-ARM; METASTATIC MELANOMA; IMPROVED SURVIVAL; RAF INHIBITION; LOW-GRADE; VEMURAFENIB; PHASE-2;

D O I：

10.1016/j.esmoop.2023.100788

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BRAF activation occurs as part of the mitogen-activated protein kinase (MAPK) cellular signaling pathway which leads to increased cellular proliferation and survival. Mutations in BRAF can result in unbridled activation of downstream kinases with subsequent uncontrolled cellular growth that formulate the basis for oncogenesis in multiple tumor types. Targeting BRAF by selective inhibitors has been one of the early successes in precision oncology. Agents have been explored either as monotherapy or in combination with MEK inhibition in BRAF V600-mutant pan-cancers and with EGFR inhibition in colorectal cancer. Spectrum of BRAF inhibition has evolved from being melanoma-specific to being a pan-cancer target. In this article, we review BRAF and MEK inhibitor drug development journey from tissuespecific melanoma, non-small-cell lung cancer, and anaplastic thyroid cancer to tissue-agnostic approvals. Key words: BRAF, MEK, cancer, precision oncology, targeted therapy

引用

页数：15

共 87 条

[1] Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant Tumors [J].

Adashek, Jacob J. ;

Menta, Arjun K. ;

Reddy, Neha K. ;

Desai, Aakash P. ;

Roszik, Jason ;

Subbiah, Vivek .

MOLECULAR CANCER THERAPEUTICS, 2022, 21 (06) :871-878

[2] AACR Project GENIE: Powering Precision Medicine through an International Consortium [J].

Andre, Fabrice ;

Arnedos, Monica ;

Baras, Alexander S. ;

Baselga, Jose ;

Bedard, Philippe L. ;

Berger, Michael F. ;

Bierkens, Mariska ;

Calvo, Fabien ;

Cerami, Ethan ;

Chakravarty, Debyani ;

Dang, Kristen K. ;

Davidson, Nancy E. ;

Del Vecchio, Fitz Catherine ;

Dogan, Semih ;

DuBois, Raymond N. ;

Ducar, Matthew D. ;

Futreal, P. Andrew ;

Gao Jianjiong ;

Garcia, Francisco ;

Gardos, Stu ;

Gocke, Christopher D. ;

Gross, Benjamin E. ;

Guinney, Justin ;

Heins, Zachary J. ;

Hintzen, Stephanie ;

Horlings, Hugo ;

Hudecek, Jan ;

Hyman, David M. ;

Kamel-Reid, Suzanne ;

Kandoth, Cyriac ;

Kinyua, Walter ;

Kumari, Priti ;

Kundra, Ritika ;

Ladanyi, Marc ;

Lefebvre, Celine ;

LeNoue-Newton, Michele L. ;

Lepisto, Eva M. ;

Levy, Mia A. ;

Lindeman, Neal, I ;

Lindsay, James ;

Liu, David ;

Lu Zhibin ;

MacConaill, Laura E. ;

Ian, Maurer ;

Maxwell, David S. ;

Meijer, Gerrit A. ;

Meric-Bernstam, Funda ;

Micheel, Christine M. ;

Miller, Clinton ;

Mills, Gordon .

CANCER DISCOVERY, 2017, 7 (08) :818-831

[3]

[Anonymous], 2019, FDA GRANTS ACCELERAT

[4]

[Anonymous], CLINICALTRIALS

[5]

[Anonymous], 2020, FDA

[6] 5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study [J].

Ascierto, Paolo A. ;

Dreno, Brigitte ;

Larkin, James ;

Ribas, Antoni ;

Liszkay, Gabriella ;

Maio, Michele ;

Mandala, Mario ;

Demidov, Lev ;

Stroyakovskiy, Daniil ;

Thomas, Luc ;

de la Cruz-Merino, Luis ;

Atkinson, Victoria ;

Dutriaux, Caroline ;

Garbe, Claus ;

Hsu, Jessie ;

Jones, Surai ;

Li, Haocheng ;

McKenna, Edward ;

Voulgari, Athina ;

McArthur, Grant A. .

CLINICAL CANCER RESEARCH, 2021, 27 (19) :5225-5235

[7] Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial [J].

Ascierto, Paolo A. ;

McArthur, Grant A. ;

Dreno, Brigitte ;

Atkinson, Victoria ;

Liszkay, Gabrielle ;

Di Giacomo, Anna Maria ;

Mandala, Mario ;

Demidov, Lev ;

Stroyakovskiy, Daniil ;

Thomas, Luc ;

de la Cruz-Merino, Luis ;

Dutriaux, Caroline ;

Garbe, Claus ;

Yan, Yibing ;

Wongchenko, Matthew ;

Chang, Ilsung ;

Hsu, Jessie J. ;

Koralek, Daniel O. ;

Rooney, Isabelle ;

Ribas, Antoni ;

Larkin, James .

LANCET ONCOLOGY, 2016, 17 (09) :1248-1260

[8] Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies [J].

Bhatty, Minny ;

Kato, Shumei ;

Piha-Paul, Sarina A. ;

Naing, Aung ;

Subbiah, Vivek ;

Huang, Helen J. ;

Karp, Daniel D. ;

Tsimberidou, Apostolia M. ;

Zinner, Ralph G. ;

Hwu, Wen-Jen ;

Javle, Milind ;

Patel, Sapna P. ;

Hu, Mimi, I ;

Varadhachary, Gauri R. ;

Conley, Anthony P. ;

Ramzanali, Nishma M. ;

Holley, Veronica R. ;

Kurzrock, Razelle ;

Meric-Bernstam, Funda ;

Chae, Young Kwang ;

Kim, Kevin B. ;

Falchook, Gerald S. ;

Janku, Filip .

CANCER, 2019, 125 (03) :463-472

[9] Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma [J].

Bollag, Gideon ;

Hirth, Peter ;

Tsai, James ;

Zhang, Jiazhong ;

Ibrahim, Prabha N. ;

Cho, Hanna ;

Spevak, Wayne ;

Zhang, Chao ;

Zhang, Ying ;

Habets, Gaston ;

Burton, ElizabethA. ;

Wong, Bernice ;

Tsang, Garson ;

West, Brian L. ;

Powell, Ben ;

Shellooe, Rafe ;

Marimuthu, Adhirai ;

Nguyen, Hoa ;

Zhang, Kam Y. J. ;

Artis, Dean R. ;

Schlessinger, Joseph ;

Su, Fei ;

Higgins, Brian ;

Iyer, Raman ;

D'Andrea, Kurt ;

Koehler, Astrid ;

Stumm, Michael ;

Lin, Paul S. ;

Lee, Richard J. ;

Grippo, Joseph ;

Puzanov, Igor ;

Kim, Kevin B. ;

Ribas, Antoni ;

McArthur, Grant A. ;

Sosman, Jeffrey A. ;

Chapman, Paul B. ;

Flaherty, Keith T. ;

Xu, Xiaowei ;

Nathanson, Katherine L. ;

Nolop, Keith .

NATURE, 2010, 467 (7315) :596-599

[10] Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600-Mutant Low-Grade Glioma [J].

Bouffet, Eric ;

Geoerger, Birgit ;

Moertel, Christopher ;

Whitlock, James A. ;

Aerts, Isabelle ;

Hargrave, Darren ;

Osterloh, Lisa ;

Tan, Eugene ;

Choi, Jeea ;

Russo, Mark ;

Fox, Elizabeth .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (03) :664-+

← 1 2 3 4 5 6 7 8 9 →